The patients with Nu-PANX2-positive CCRCC had a 3.186-fold (95% CI; 1.450–7.002) greater risk of cancer-related death and a 2.302-fold (95% CI; 1.180–4.492) greater risk of relapse or cancer-related death compared with the patients with Nu-PANX2-negative CCRCC. Here, PANX2 is linked to cancer.